Substance / Medication

Methapyrilene

Overview

Active Ingredient
methapyrilene
RxNorm CUI
6822

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Editor's Highlight: Organ-Specific Epigenetic Changes Induced by the Nongenotoxic Liver Carcinogen Methapyrilene in Fischer 344 Rats.
Shpyleva Svitlana, Dreval Kostiantyn, de Conti Aline et al. · Toxicol Sci · 2017
PMID: 28013212Observational
Interlaboratory evaluation of rat hepatic gene expression changes induced by methapyrilene.
Waring Jeffrey F, Ulrich Roger G, Flint Nick et al. · Environ Health Perspect · 2004
PMID: 15033593ObservationalFull text (PMC)
Effect of aflatoxin B, benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells.
Tryndyak Volodymyr, Kindrat Iryna, Dreval Kostiantyn et al. · Food Chem Toxicol · 2018
PMID: 30157460Other
An investigation of the plasma and urinary metabolite profiles of the hepatotoxin methapyrilene in the male Wistar rat.
Plumb Robert S, Lai Steven K, Gethings Lee A et al. · J Pharm Biomed Anal · 2025
PMID: 40435660Preclinical
Application of duplex sequencing to evaluate mutagenicity of aristolochic acid and methapyrilene in Fisher 344 rats.
Sahib Seaab, Yan Jian, Chen Tao · Food Chem Toxicol · 2024
PMID: 38342231Preclinical
Effect of microsampling (50 μL) on toxicological evaluation of methapyrilene, a hepatotoxic substance, in a collaborative 28-day study in female rats.
Hattori Norimichi, Yokoyama Hideaki, Takumi Asuka et al. · J Toxicol Sci · 2023
PMID: 36599423Preclinical
In vitro proteomic analysis of methapyrilene toxicity in rat hepatocytes reveals effects on intermediary metabolism.
Braeuning Albert, Oberemm Axel, Heise Tanja et al. · Arch Toxicol · 2019
PMID: 30467583Preclinical
Effect of methapyrilene hydrochloride on hepatic intracellular iron metabolism in vivo and in vitro.
Kindrat Iryna, Dreval Kostiantyn, Shpyleva Svitlana et al. · Toxicol Lett · 2017
PMID: 28935588Preclinical
Quantitative targeted bile acid profiling as new markers for DILI in a model of methapyrilene-induced liver injury in rats.
Slopianka Markus, Herrmann Anne, Pavkovic Mira et al. · Toxicology · 2017
PMID: 28529062Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Methapyrilene (substance)
SNOMED CT
59338009
UMLS CUI
C0025625
RxNorm CUI
6822

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.